Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells

Cancer

Volumn 117, Issue 4, 2011, Pages 784-794

  Tan, Lijun ^a   Kwok, Roland P ^a   Shukla, Abhishek ^a   Kshirsagar, Malti ^a   Zhao, Lili ^a   Opipari Jr , Anthony W ^a   Liu, J Rebecca ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apaf 1; apoptosome; chemoresistance; histone deacetylase inhibitor; ovarian carcinoma

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 9; CISPLATIN; CYTOCHROME C; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; APOPTOSOME;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL CELL; APAF 1 GENE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; ONCOGENE; OVARIAN CANCER CELL LINE; PHENOTYPE;

ANTINEOPLASTIC AGENTS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CASPASE 9; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; OVARIAN NEOPLASMS;

EID: 79551706245     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25649     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
2. Hajra KM, Liu JR., Apoptosome dysfunction in human cancer. Apoptosis. 2004; 9: 691-704.
3. Liu JR, Opipari AW, Tan L, et al. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 2002; 62: 924-931.
4. Garcia-Manero G, Issa JP., Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest. 2005; 23: 635-642.
5. Ashburner BP, Westerheide SD, Baldwin AS, Jr,. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol. 2001; 21: 7065-7077.
6. Zlobec I, Vuong T, Compton CC., The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy. Cancer. 2006; 106: 284-286.
7. Zlobec I, Minoo P, Baker K, et al. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer. 2007; 43: 1101-1107.
8. Merino R, Grillot DA, Simonian PL, et al. Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction. J Immunol. 1995; 155: 3830-3838.
9. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2005; 102: 3697-3702.
10. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA., Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis. 2004; 9: 573-582.
11. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001; 409: 207-211.
12. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H., Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res. 2005; 3: 325-334.
13. Sun Y, Orrenius S, Pervaiz S, Fadeel B., Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B-lymphoma cells: a novel mechanism of chemoresistance. Blood. 2005; 105: 4070-4077.
14. Kamarajan P, Sun NK, Sun CL, Chao CC., Apaf-1 overexpression partially overcomes apoptotic resistance in a cisplatin-selected HeLa cell line. FEBS Lett. 2001; 505: 206-212.
15. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006; 66: 5781-5789.
16. Minucci S, Pelicci PG., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6: 38-51.
17. Bots M, Johnstone RW., Rational combinations using HDAC inhibitors. Clin Cancer Res. 2009; 15: 3970-3977.
18. Bolden JE, Peart MJ, Johnstone RW., Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-784.
19. Frew AJ, Johnstone RW, Bolden JE., Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009; 280: 125-133.